medigraphic.com

2007, Number 4

<< Back Next >>

Enf Infec Microbiol 2007; 27 (4)

In vitro antimicrobial activity of tigecycline against some clinically relevant Gram-positive and Gram-negative species isolated in Mexico

Garza GE, Bosques PFJ, González GM, Quintanilla VF, Llanca DJ

Language: Spanish
References: 17
Page: 118-126
PDF size: 83.44 Kb.


ABSTRACT

The in vitro activity of tigecycline and other antimicrobial agents was determined against 175 bacterial strains representing different species or phenotypic groups isolated in Mexico. Susceptibility testing was performed by Minimum inhibitory concentration (MIC) by a broth microdilution method using MicroScan panels.
Tigecycline exhibited excellent activity against all Gram-positive bacteria, with MIC91 values ≤ 0.5 mg/L, including for methicillin resistant Staphylococcus aureus (MRSA), and Streptococcus pneumoniae resistant to penicillin. Good activity was noted for the majority of the Enterobacteriaceae species (MIC90 0.5-2 mg/L) and Acinetobacter baumannii (MIC90 0.5 mg/L).
Tigecycline exhibited a potent antimicrobial activity against a wide variety of clinically important bacteria pathogens and was frequently more active than other antimicrobial compounds. The results of this study suggest that tigecycline could be an excellent alternative for the treatment of infections related to a wide range of Gram-positive and Gram-negative bacterial pathogens, including the multiresistant nosocomial pathogens A. baumannii and MRSA.


REFERENCES

  1. Fish DN, Ohlinger MJ. “Antimicrobial resistance: factors and outcomes.” Crit Care Clin 2006;22:291-311.

  2. Smith MA, McInnis LA. “Antimicrobial resistance in critical care.” Crit Care Nurs Clin North Am 2007;19:53-60.

  3. Frimodt-Moller N, Hammerum AM, Bagger-Skjot L et al. ”Global development of resistance--secondary publication.” Dan Med Bul 2007;54:160-162.

  4. Zhanel GG, Homenuik K, Nichol K et al. “The glycylcyclines: a comparative review with the tetracyclines.” Drugs 2004;64:63-88.

  5. Petersen PJ, Jacobus NV, Weiss WJ, Sum PE, Testa RT. “In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936).” Antimicrob Agents Chemother 1999;43:738-744.

  6. Hoban DJ, Bouchillon SK, Johnson BM, Johnson JL, Dowzicky MJ; “Tigecycline Evaluation and Surveillance Trial (TEST Program) Group. In vitro activity of tigecycline against 6792 Gram-negative and Grampositive clinical isolates from the global Tigecycline Evaluation and Surveillance Trial (TEST Program, 2004).” Diagn Microbiol Infect Dis 2005;52:215-227.

  7. Fritsche TR, Jones RN. “Antimicrobial activity of tigecycline (GAR-936) tested against 3498 recent isolates of Staphylococcus aureus recovered from osocomial and community-acquired infections.” Int J Antimicrob Agents. 2004;24:567-571.

  8. Stevens DL, Bisno AL, Chambers HF et al. “Infectious Diseases Society of America. Practice guidelines for the diagnosis and management of skin and soft-tissue infections.” Clin Infect Dis 2005;41:1373-1406.

  9. Wyeth Pharmaceutics. “Tygacil (Tigecycline) for Injection [package insert].” Philadelphia, PA: Wyeth Pharmaceuticals Inc; 2005.

  10. Hawkey P, Finch R. “Tigecycline: in-vitro performance as a predictor of clinical efficacy.” Clin Microbiol Infect 2007;13:354-362.

  11. Fomin P, Beuran M, Gradauskas A et al. “Tigecycline is efficacious in the treatment of complicated intra-abdominal infections.” Int J Surg 2005;3:35-47.

  12. Garrison MW, Nuemiller JJ. “In vitro activity of tigecycline against quinolone-resistant Streptococcus pneumoniae, methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci.” Int J Antimicrob Agents 2007;29:191-196.

  13. Slover CM, Rodvold KA, Danziger LH. ”Tigecycline: a novel broad-spectrum antimicrobial.” Ann Pharmacother 2007;41:965-972.

  14. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7-A6. Wayne, PA: NCCLS, 2003.

  15. Murray CK, Hospenthal DR. “Treatment of multidrug resistant Acinetobacter.” Curr Opin Infect Dis 2005;18:502-506.

  16. Curcio D, Fernandez F. “Acinetobacter spp. susceptibility to tigecycline: a worldwide perspective.” J Antimicrob Chemother 2007 Jun 7;[Epub ahead of print].

  17. Halstead DC, Abid J, Dowzicky MJ. “Antimicrobial susceptibility among Acinetobacter calcoaceticusbaumannii complex and Enterobacteriaceae collected as part of the Tigecycline Evaluation and Surveillance Trial.” J Infect 2007;55:49-57.




2020     |     www.medigraphic.com